Modus Therapeutics completes directed issue raising MSEK 7.6
KDventures AB says its portfolio company Modus Therapeutics carried out a directed issue of MSEK 7.6. Net proceeds will finance the 2027 development plan for sevuparin.
STOCKHOLM, SWEDEN September 4, 2026.
KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company Modus Therapeutics has carried out a directed issue of MSEK 7.6.
The net proceeds will finance the company’s development plan for the drug candidate sevuparin during 2027.Investors in the…